Clear cell carcinoma of the ovary: Is there a role of histology-specific treatment?

Journal of Experimental and Clinical Cancer Research

Volumn 31, Issue 1, 2012, Pages

  Takano, Masashi ^a   Tsuda, Hiroshi ^b   Sugiyama, Toru ^c  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^b KEIO UNIVERSITY   (Japan)

^c IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

Chemotherapy; Clear cell carcinoma; Fertility sparing; Molecular targeting agents; Ovarian cancer; Review; Surgical staging

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; ETOPOSIDE; GEMCITABINE; GLUTAREDOXIN; GLUTATHIONE PEROXIDASE 3; HEPATOCYTE NUCLEAR FACTOR 1; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; IRINOTECAN; MANGANESE SUPEROXIDE DISMUTASE; MEGESTROL ACETATE; PACLITAXEL; TEMSIROLIMUS;

ADJUVANT CHEMOTHERAPY; ADVANCED CANCER; ASCITES; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CLEAR CELL CARCINOMA; CYSTADENOCARCINOMA; CYTOREDUCTIVE SURGERY; DRUG EFFECT; DRUG MONITORING; ENDOMETRIUM; FERTILITY; FERTILITY SPARING SURGERY; GENE EXPRESSION; HISTOLOGY; HUMAN; HYSTERECTOMY; IN VITRO STUDY; INTRAOPERATIVE PERIOD; LIVER METASTASIS; LYMPH NODE METASTASIS; LYMPHADENECTOMY; OMENTECTOMY; OVARY CARCINOMA; PERITONEUM METASTASIS; PHASE 2 CLINICAL TRIAL (TOPIC); POSTOPERATIVE CARE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; QUALITY OF LIFE; REVIEW; SALPINGOOOPHORECTOMY; TREATMENT RESPONSE; UPREGULATION;

ADENOCARCINOMA, CLEAR CELL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FERTILITY PRESERVATION; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM STAGING; OVARIAN NEOPLASMS;

EID: 84861682969     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-31-53     Document Type: Review

References (61)

1. Lymph node metastasis in ovarian cancer: difference between serous and non-serous primary tumors. Takeshima N, Hirai Y, Umayahara K, et al. Gynecol Oncol 2005 99 427 431 10.1016/j.ygyno.2005.06.051 16112718 (Pubitemid 41502856)
2. Pelvic and para-aortic lymphadenectomy in cancer of the ovary. Di Re F, Fontanelli R, Raspagliesi F, et al. Baillieres Clin Obstet Gynaecol 1989 3 131 142 10.1016/S0950-3552(89)80048-3 2661087 (Pubitemid 19183100)
3. Lymphadenectomy in stage I ovarian cancer. Petru E, Lahousen M, Tamussino K, et al. Am J Obstet Gynecol 1994 170 656 662 8116728 (Pubitemid 24089032)
4. Assessment of metastases to aortic and pelvic lymph nodes in epithelial ovarian carcinoma, A proposal for essential sites for lymph node biopsy. Onda T, Yoshikawa H, Yokota H, et al. Cancer 1996 78 803 808 10.1002/(SICI)1097- 0142(19960815)78:4<803::AID-CNCR17>3.0.CO;2-Z 8756375 (Pubitemid 26268611)
5. Systematic pelvic and paraaortic lymphadenectomy at second-look laparotomy for ovarian cancer. Baiocchi G, Grosso G, di Re E, et al. Gynecol Oncol 1998 69 151 156 10.1006/gyno.1998.4964 9600823 (Pubitemid 28247002)
6. Lymph node metastasis in stage I epithelial ovarian cancer. Suzuki M, Ohwada M, Yamada T, et al. Gynecol Oncol 2000 79 305 308 10.1006/gyno.2000.5951 11063662
7. Prognostic significance of lymph node metastasis and clear cell histology in ovarian carcinoma limited to the pelvis (pT1M0 and pT2M0). Sakuragi N, Yamada H, Oikawa M, et al. Gynecol Oncol 2000 79 251 255 10.1006/gyno.2000.5933 11063653
8. Lymphatic mapping and sentinel node identification as related to the primary sites of lymph node metastasis in early stage ovarian cancer. Negishi H, Takeda M, Fujimoto T, et al. Gynecol Oncol 2004 94 161 166 10.1016/j.ygyno. 2004.04.023 15262135 (Pubitemid 38950513)
9. Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging. Takano M, Kikuchi Y, Yaegashi N, et al. Br J Cancer 2006 94 1369 1374 10.1038/sj.bjc.6603116 16641903 (Pubitemid 43772268)
10. Pattern and clinical predictors of lymph node metastases in epithelial ovarian cancer. Harter P, Gnauert K, Hils R, et al. Int J Gynecol Cancer 2007 17 1238 1244 10.1111/j.1525-1438.2007.00931.x 17433064 (Pubitemid 350077354)
11. Lymph node metastasis in grossly apparent clinical stage Ia epithelial ovarian cancer: Hacettepe experience and review of literature. Desteli GA, Gultekin M, Usubutun A, et al. World J Surg Oncol 2010 8 106 10.1186/1477-7819-8-106 21114870
12. Lymph node metastasis in grossly apparent stages I and II epithelial ovarian cancer. Nomura H, Tsuda H, Susumu N, et al. Int J Gynecol Cancer 2010 20 341 345 10.1111/IGC.0b013e3181cf6271 20375794
13. Lymph node involvement in epithelial ovarian cancer: analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications. Morice P, Joulie F, Camatte S, et al. J Am Coll Surg 2003 197 198 205 10.1016/S1072- 7515(03)00234-5 12892797 (Pubitemid 36927382)
14. The validity and significance of substage IIIC by node involvement in epithelial ovarian cancer: impact of nodal metastasis on patient survival. Kanazawa K, Suzuki T, Tokashiki M, Gynecol Oncol 1998 73 237 241 (Pubitemid 29215737)
15. Surgical and medical treatment of clear cell ovarian cancer: results from the multicenter Italian Trials in Ovarian Cancer (MITO) 9 retrospective study. Magazzino F, Katsaros D, Ottaiano A, et al. Int J Gynecol Cancer 2011 21 1063 1070 10.1097/IGC.0b013e318218f270 21633300
16. Less impact of adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study. Takano M, Sugiyama T, Yaegashi N, et al. Int J Gynecol Cancer 2010 20 1506 1510 21119366
17. Association of lymphadenectomy and survival in stage I ovarian cancer patients. Chan JK, Munro EG, Cheung MK, et al. Obstet Gynecol 2007 109 12 19 10.1097/01.AOG.0000249610.95885.ef 17197582 (Pubitemid 46043192)
18. Is there any association between retroperitoneal lymphadenectomy and survival benefit in ovarian clear cell carcinoma patients? Suzuki S, Kajiyama H, Shibata K, et al. Ann Oncol 2008 19 1284 1287 10.1093/annonc/mdn059 18356137 (Pubitemid 351911958)
19. Survival impact of capsule rupture in stage I clear cell carcinoma of the ovary in comparison with other histological types. Higashi M, Kajiyama H, Shibata K, et al. Gynecol Oncol 2011 123 474 478 10.1016/j.ygyno.2011.08.036 21955484
20. Clear cell carcinoma compared to serous carcinoma in early ovarian cancer: same prognosis in a large randomized trial. Timmers PJ, Zwinderman AH, Teodorovic I, et al. Int J Gynecol Cancer 2009 19 88 93 10.1111/IGC. 0b013e3181991546 19258948
21. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Hoskins WJ, Bundy BN, Thigpen JT, et al. Gynecol Oncol 1992 47 159 166 10.1016/0090-8258(92)90100-W 1468693 (Pubitemid 23001322)
22. Survival probability in ovarian clear cell adenocarcinoma. Kennedy AW, Markman M, Biscotti CV, et al. Gynecol Oncol 1999 74 108 114 10.1006/gyno.1999.5445 10385560 (Pubitemid 29331176)
23. Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy. Schilder JM, Thompson AM, DePriest PD, et al. Gynecol Oncol 2002 87 1 7 10.1006/gyno.2002.6805 12468335 (Pubitemid 36027095)
24. Is there any possibility of fertility-sparing surgery in patients with clear-cell carcinoma of the ovary? Kajiyama H, Shibata K, Suzuki S, et al. Gynecol Oncol 2008 111 523 526 10.1016/j.ygyno.2008.04.001 18538833
25. Outcomes of fertility-sparing surgery for stage I epithelial ovarian cancer: a proposal for patient selection. Satoh T, Hatae M, Watanabe Y, et al. J Clin Oncol 2010 28 1727 1732 10.1200/JCO.2009.24.8617 20194858
26. Fertility-sparing surgery in patients with clear-cell carcinoma of the ovary: Is it possible? Kajiyama H, Shibata K, Mizuno M, et al. Hum Reprod 2011 26 3297 3302 10.1093/humrep/der342 22016417
27. Clear cell epithelial ovarian cancer (mesonephroid): bad prognosis only in early stages. O'Brien ME, Schofield JB, Tan S, et al. Gynecol Oncol 1993 49 250 254 10.1006/gyno.1993.1117 8504995 (Pubitemid 23170001)
28. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. Omura GA, Brady MF, Homesley HD, et al. J Clin Oncol 1991 9 1138 1150 1904477
29. Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Goff BA, Sainz De La Cuesta R, Muntz HG, et al. Gynecol Oncol 1996 60 412 417 10.1006/gyno.1996.0065 8774649 (Pubitemid 26077628)
30. Irinotecan (CPT-11) combined with cisplatin in patients with refractory or recurrent ovarian cancer. Sugiyama T, Yakushiji M, Nishida T, et al. Cancer Lett 1998 128 211 218 10.1016/S0304-3835(98)00065-2 9683285 (Pubitemid 28318738)
31. Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease. Ho CM, Huang YJ, Chen TC, et al. Gynecol Oncol 2004 94 197 203 10.1016/j.ygyno.2004.04.004 15262142 (Pubitemid 38950520)
32. Is clear cell carcinoma and mucinous carcinoma of the ovary sensitive to combination chemotherapy with paclitaxel and carboplatin? Enomoto T, Kuragaki C, Yamasaki M, Proc Am Soc Clin Oncol 2003 22 #1797 447
33. Paclitaxel-platinum combination chemotherapy for advanced or recurrent ovarian clear cell adenocarcinoma: a multicenter trial. Utsunomiya H, Akahira J, Tanno S, et al. Int J Gynecol Cancer 2006 16 52 56 10.1111/j.1525-1438.2006. 00289.x 16445610
34. Synergistic enhancement of cisplatin cytotoxicity by SN-38, an active metabolite of CPT-11, for cisplatin-resistant HeLa cells. Minagawa Y, Kigawa J, Ishihara H, et al. Jpn J Cancer Res 1994 85 966 971 10.1111/j.1349-7006.1994. tb02976.x 7961127 (Pubitemid 24294757)
35. Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells. Fukuda M, Nishio K, Kanzawa F, et al. Cancer Res 1996 56 789 793 8631015
36. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. Noda K, Nishiwaki Y, Kawahara M, et al. N Engl J Med 2002 346 85 91 10.1056/NEJMoa003034 11784874 (Pubitemid 34438898)
37. A pilot study of CPT-11 and cisplatin for ovarian clear cell adenocarcinoma. Adachi S, Ogasawara T, Yamasaki N, et al. Jpn J Clin Oncol 1999 29 434 437 10.1093/jjco/29.9.434 10563197
38. Exploratory study of effective chemotherapy to clear cell carcinoma of the ovary. Kita T, Kikuchi Y, Kudoh K, et al. Oncol Rep 2000 7 327 331 10671681
39. Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis. Takano M, Sugiyama T, Yaegashi N, et al. Int J Clin Oncol 2007 12 256 260 10.1007/s10147-007-0670-1 17701003 (Pubitemid 47262735)
40. Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG study. Takakura S, Takano M, Takahashi F, et al. Int J Gynecol Cancer 2010 20 240 247 10.1111/IGC.0b013e3181cafb47 20169667
41. http://www.gcig.igcs.org/files/JGOG3017-Protocol.pdf: accessed on April 16, 2012
42. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Parmar MK, Ledermann JA, Colombo N, et al. Lancet 2003 361 2099 2106 12826431
43. Treatment options in the management of ovarian cancer. Kikuchi Y, Kita T, Takano M, et al. Expert Opin Pharmacother 2005 6 743 754 10.1517/14656566.6.5. 743 15934901 (Pubitemid 40711770)
44. Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary. Crotzer DR, Sun CC, Coleman RL, et al. Gynecol Oncol 2007 105 404 408 10.1016/j.ygyno.2006.12.024 17292461 (Pubitemid 46590333)
45. Low response rate of second-line chemotherapy for recurrent or refractory clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study. Takano M, Sugiyama T, Yaegashi N, et al. Int J Gynecol Cancer 2008 18 937 942 10.1111/j.1525-1438.2007.01158.x 18081792
46. Phase II study of high-dose megestrol acetate in platinum-refractory epithelial ovarian cancer. Wilailak S, Linasmita V, Srisupundit S, Anticancer Drugs 2001 12 719 724 10.1097/00001813-200110000-00002 11593052 (Pubitemid 33001184)
47. Weekly administration of temsirolimus for heavily pretreated patients with clear cell carcinoma of the ovary: a report of six cases. Takano M, Kikuchi Y, Kudoh K, et al. Int J Clin Oncol 2011 16 605 609 10.1007/s10147-010-0177-z 21243393
48. Salvage chemotherapy for recurrent or persistent clear cell carcinoma of the ovary: a single-institution experience for a series of 20 patients. Yoshino K, Enomoto T, Fujita M, et al. Int J Clin Oncol in press in press
49. p53 mutation is infrequent in clear cell carcinoma of the ovary. Ho ES, Lai CR, Hsieh YT, et al. Gynecol Oncol 2001 80 189 193 10.1006/gyno.2000.6025 11161858 (Pubitemid 32158457)
50. p53 mutations and overexpression affect prognosis of ovarian endometrioid cancer but not clear cell cancer. Okuda T, Otsuka J, Sekizawa A, et al. Gynecol Oncol 2003 88 318 325 10.1016/S0090-8258(02)00149-X 12648581 (Pubitemid 36331984)
51. Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance. Salani R, Kurman RJ, Giuntoli R, et al. Int J Gynecol Cancer 2008 18 487 491 10.1111/j.1525-1438.2007.01039.x 17692090 (Pubitemid 351668307)
52. Coordinately up-regulated genes in ovarian cancer. Hough CD, Cho KR, Zonderman AB, et al. Cancer Res 2001 61 3869 3876 11358798 (Pubitemid 32720943)
53. Identification of overexpression and amplification of ABCF2 in clear cell ovarian adenocarcinomas by cDNA microarray analyses. Tsuda H, Ito YM, Ohashi Y, et al. Clin Cancer Res 2005 11 6880 6888 10.1158/1078-0432.CCR-05-0751 16203778 (Pubitemid 41428744)
54. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Schwartz DR, Kardia SL, Shedden KA, et al. Cancer Res 2002 62 4722 4729 12183431
55. Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Tsuchiya A, Sakamoto M, Yasuda J, et al. Am J Pathol 2003 163 2503 2512 10.1016/S0002-9440(10)63605-X 14633622 (Pubitemid 37466491)
56. Expression of hepatocyte nuclear factor-1beta (HNF-1beta) in clear cell tumors and endometriosis of the ovary. Kato N, Sasou S, Motoyama T, Mod Pathol 2006 19 83 89 10.1038/modpathol.3800492 16258507 (Pubitemid 43250982)
57. Over-expression of hypoxia-inducible factor 1 alpha in ovarian clear cell carcinoma. Lee S, Garner EI, Welch WR, et al. Gynecol Oncol 2007 106 311 317 10.1016/j.ygyno.2007.03.041 17532031 (Pubitemid 47087928)
58. Therapeutic strategy targeting the mTOR-HIF-1alpha-VEGF pathway in ovarian clear cell adenocarcinoma. Miyazawa M, Yasuda M, Fujita M, et al. Pathol Int 2009 59 19 27 10.1111/j.1440-1827.2008.02320.x 19121088
59. mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary. Mabuchi S, Kawase C, Altomare DA, et al. Clin Cancer Res 2009 15 5404 5413 10.1158/1078-0432.CCR-09- 0365 19690197
60. Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Clear Cell Ovarian Cance http://clinicaltrials.gov/ct2/show/NCT01196429, accessed on April 16, 2012
61. Sunitinib Malate in Treating Patients With Persistent or Recurrent Clear Cell Ovarian Cancer http://clinicaltrials.gov/ct2/show/NCT00979992: accessed on April 16, 2012